Home / Who we serve

Life sciences

Target accounts on ground truth, not year-old directories

Launch plans and field teams directed by where care is actually delivered today — and where systems are investing next.

Who this serves

Major pharma, biotech, CROs, biomanufacturers, medical device, diagnostics.

What this means for your strategy
  • Sequence launches and direct field teams with a live map of where care is delivered — by system, site, and specialty
  • Spot which health systems are investing in your therapeutic area — through hiring, capacity requests, and capital plans — before it is public news
  • Size and prioritize markets with evidence that stands up in board and investor reviews
The quality behind it
  • A national census of care sites — hospital to infusion and ambulatory — re-verified monthly, so closed or relocated sites never burn field time
  • Investment signals triangulated across three independent lenses: hiring, regulatory filings, and lender disclosures
  • Every site tied to system ownership, so signals roll up to the enterprise account your team actually calls on
Why AI alone can’t replicate it
  • Commercial directories run 12–24 months stale — AI trained on the public web inherits that staleness and cannot tell an open site from a closed one
  • Early investment signals exist only if someone was watching when they appeared; postings and filings are removed and overwritten
  • Blending these three signal families into one account view takes healthcare judgment AI alone lacks
By the numbers
Monthlyre-verification of the national care-site map, with history
3 lensesindependent signals per account: hiring, regulatory, financial
600+health systems monitored daily for hiring investment signals
160+health systems with lender-disclosure intelligence
Editions for this seat

Request access Browse the full catalog